-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Utilizing interim Phase II results to streamline Phase III development: what does the future hold?
Jie Huang
Editorial: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Inclusion of older people in interventional clinical trials
Prabhath Fernando, Amit Arora, Peter Crome
Clinical Trail Perspective: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Hypocretin receptor antagonists for insomnia: rationale and clinical data
Chad Ruoff, Christian Guilleminault
Review: Clinical Trail Outcomes: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation
-
Oral antiretroviral therapy for the prevention of HIV-1 infection: ready for prime-time?
Mark W Hull, Julio SG Montaner
Editorial: Clinical Investigation